10.6084/m9.figshare.4560790.v1
Aherfi S.
Aherfi
S.
Glazunova O.
Glazunova
O.
Borentain P.
Borentain
P.
Botta-Fridlund D.
Botta-Fridlund
D.
Chiche L.
Chiche
L.
Bregigeon S.
Bregigeon
S.
Motte A.
Motte
A.
Tamalet C.
Tamalet
C.
Colson P.
Colson
P.
Supplementary Material for: Hepatitis C Virus of Subtype 2l in Marseille, Southeastern France
Karger Publishers
2017
Hepatitis C virus
Genotype
Subtype 2l
Treatment
Polymerase
2017-01-18 15:25:41
Dataset
https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Hepatitis_C_Virus_of_Subtype_2l_in_Marseille_Southeastern_France/4560790
<p>The rate of eradication of chronic hepatitis C considerably increases
with direct-acting antiviral agents, particularly hepatitis C virus
(HCV) polymerase inhibitors. While implementing full-length HCV NS5B
polymerase sequencing in our clinical microbiology laboratory, we
identified atypical HCV sequences, classified as subtype 2l, from 2
patients. HCV-2l NS5B polymerase sequences were detected from 5 and 14
additional patients by screening our laboratory hepatitis virus sequence
database and the NCBI GenBank sequence database. Phylogenetic analyses
show unambiguously that all HCV-2l sequences are clustered apart from
HCV 2 non-l sequences, which compose a second cluster. Mean (±SD)
nucleotide identity between near full-length NS5B fragments of subtype
2l was 93.4 ± 0.8% (range: 92.4-95.1). Of note, all HCV-2l sequences
obtained in our laboratory and in other centers were from serum samples
collected in France. Analysis of the HCV-2l NS5B polymerase amino acid
sequences at 30 positions critical for interaction with or resistance to
HCV polymerase inhibitors showed specific patterns.</p>